| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $115.4M | +11.1% |
| SG&A Expense | $41.7M | +10.7% |
| Operating Income | -$179.6M | -26.9% |
| Net Income | -$161.7M | -29.3% |
| EPS (Basic) | -$0.69 | +16.9% |
| EPS (Diluted) | -$0.69 | +16.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $67.7M | -27.2% |
| Short-term Investments | $230.6M | +5.2% |
| Current Assets | $308.8M | -3.7% |
| Total Assets | $502.5M | +27.1% |
| Current Liabilities | $31.4M | +20.0% |
| Total Liabilities | $79.0M | +0.5% |
| Stockholders' Equity | $423.5M | +33.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$109.4M | -8.1% |
| Capital Expenditures | $60K | -96.6% |
| Investing Cash Flow | -$156.6M | -71.7% |
| Financing Cash Flow | $240.7M | — |
| Free Cash Flow | -$109.5M | -6.3% |